Supernus Pharmaceuticals Inc. said Tuesday it expects a version of its drug to treat ADHD in children to start phase 3 clinical trials next year after mid-stage trials showed positive results.
Rockville-based Supernus (NASDAQ: SUPN), which specializes in creating therapies for central nervous system diseases, said the phase 2 trials confirmed efficacy and tolerability of SPN-812, its nonstimulant attention deficit hyperactivity disorder drug, in children.
SPN-810, a version of the drug to treat…
Supernus Pharmaceuticals Inc. said Tuesday it expects a version of its drug to treat ADHD in children to start phase 3 clinical trials next year after mid-stage trials showed positive results.
Rockville-based Supernus (NASDAQ: SUPN), which specializes in creating therapies for central nervous system diseases, said the phase 2 trials confirmed efficacy and tolerability of SPN-812, its nonstimulant attention deficit hyperactivity disorder drug, in children.
SPN-810, a version of the drug to treat…